COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Favipiravir, one 200mg tablet, produced by Actover Co. (IRAN), single dose. Intervention 2: Control group: Avigan, one 200mg tablet, produced by Toyoma Chemical com
Sponsors
Actover Pharm. Co.
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: - Aged between 18 - 50 years - Body weight between 50 – 100 kg - Having good health on the basis of medical history and physical & clinical examination - Understand the procedures and give written informed consent
Exclusion criteria
Exclusion criteria: Subject had undergone surgery of the gastro-intestinal tract treatment. Subject had donated a unit of blood or participated in another clinical trial, within the last two months before the first Subject had a history of drug or alcohol abuse. Subject who smokes more than 10 cigarettes per day. Subject had used any prescription medication within 14 days, or any non-prescription medication within 7 days, before the first treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma concentration of favipiravir following administration of one tablet of 200mg favipiravir. Timepoint: at 0 (before dosing), 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0 &10.0hr. after dosing. Method of measurement: High Performance Liquid Chromatography (HPLC). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactLadan Tayebi
Pars Biopharmacy Research Co.
Outcome results
None listed